前收市價 | 0.1800 |
開市 | 0.1800 |
買盤 | 0.0200 |
賣出價 | 1.0000 |
拍板 | 138.00 |
到期日 | 2024-07-26 |
今日波幅 | 0.1800 - 0.1800 |
合同範圍 | 無 |
成交量 | |
未平倉合約 | 無 |
The medical and pharmaceutical community continues to embrace emerging technologies, beginning with mRNA that rose to fame during the COVID-19 pandemic. The beauty of mRNA technology is that it opens the door to a more personalized and effective treatment as messenger RNA instructs the patient’s cells how to combat diseases like cancer. Moderna Inc (NASDAQ: MRNA) and Merck & Co (NYSE: MRK) joined forces to advance cancer treatment with an experimental mRNA vaccine, used in combination with Merck
On Monday, Merck & Co Inc (NYSE:MRK) announced the notice of the mutual exercise of an option to convert the companies’ ongoing co-development and co-commercialization agreement for opevesostat (MK-5684/ODM-208) into an exclusive global license for Merck. As previously announced under the companies’ original co-development and co-commercialization agreement, each party was granted an option to convert the co-exclusive license into an exclusive global license for Merck. Also Read: FDA Declines To
On Thursday, the U.S. Centers for Disease Control and Prevention’s (CDC’s) Advisory Committee on Immunization Practices (ACIP) unanimously voted to recommend Merck & Co Inc’s (NYSE:MRK) Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) for adults 65 years of age and older. It is also commonly known as the pneumonia vaccine. Specifically, the ACIP voted to recommend a single dose of Capvaxive for: Adults 65 years and older who have not previously received a pneumococcal conjugate vaccine or wh